NA
CYTK icon

NewEdge Advisors’s Cytokinetics CYTK Stock Holding History

NewEdge Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Hold
119
– – ﹤0.01% 3532
2026
Q1 		$7.84K Hold
119
– – ﹤0.01% 3461
2025
Q4 		$7.56K Hold
119
– – ﹤0.01% 3553
2025
Q3 		$6.54K Hold
119
– – ﹤0.01% 3451
2025
Q2 		$3.93K Buy
+119
New +$4.14K ﹤0.01% 3473
2023
Q4 		– Sell
-78
Closed -$2.3K – 3774
2023
Q3 		$2.3K Hold
78
– – ﹤0.01% 3014
2023
Q2 		$2.54K Hold
78
– – ﹤0.01% 3023
2023
Q1 		$2.75K Hold
78
– – ﹤0.01% 2958
2022
Q4 		$4 Buy
+78
New +$3.36K ﹤0.01% 3833

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's CYTK Position: Q2 2026 in Review

NewEdge Advisors held its Cytokinetics (CYTK) position steady in Q2 2026 at 119 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3532.

NewEdge Advisors first reported a position in CYTK in Q4 2022 and has held it in 9 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • NewEdge Advisors held 119 shares of Cytokinetics worth $10.1K as of Q2 2026.
  • NewEdge Advisors left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3532 holding.
  • NewEdge Advisors first reported a position in Cytokinetics in Q4 2022 and has held it in 9 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.